Group-Based Trajectory Models to Evaluate the Association of Lipid Testing and Statin Adherence

被引:0
|
作者
Pan, Yun-Yi [1 ]
Devabhakthuni, Sandeep [1 ]
Cooke, Catherine E. [1 ]
Slejko, Julia F. [1 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Practice Sci & Hlth Outcomes Res, 220 Arch St, Baltimore, MD 21201 USA
关键词
D O I
10.1007/s40801-024-00472-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectivePerforming lipid testing after statin initiation is recommended to monitor response. Inadequate response may indicate non-adherence, which is associated with an increased risk of cardiovascular events and increased costs. Group-based trajectory modeling is an approach to establish probabilistic developmental trajectories of adherence, differentiating individuals by their distinct longitudinal medication-taking behaviors. We examined whether lipid testing is associated with distinct trajectories of statin adherence among individuals enrolled in a Medicare fee-for-service plan in the USA.MethodsA retrospective cohort study was conducted using the Centers for Medicare & Medicaid Chronic Condition Warehouse 5% sample of Medicare fee-for-service data between 2006 and 2015. Statin use and lipid testing were identified using claims data. The proportion of days covered was calculated for each 30 days after the index date, which was used to estimate the probability of belonging to each potential adherence trajectory.ResultsIn a cohort of 138,101 statin initiators, four statin adherence trajectory groups were identified. The four groups were differentiated as "rapid decline" (21.53%), "gradual decline" (10.25%), "decline first then improve later" (26.47%), and "high adherence" (41.75%). Compared with "high adherence," initiators who had lipid tests within 360 days after statin initiation were less likely to fall into "rapid decline" (adjusted odds ratio: 0.661; 95% confidence interval 0.641-0.683), "gradual decline" (adjusted odds ratio: 0.834; 95% confidence interval 0.801-0.868), and "decline first then improve later" groups (adjusted odds ratio: 0.936; 95% confidence interval 0.910-0.962).ConclusionsLipid testing is positively associated with greater use of statin medication across different adherence trajectories in the present study.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 50 条
  • [21] Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: An example using real-world statin adherence data
    Hickson, Ryan P.
    Annis, Izabela E.
    Killeya-Jones, Ley A.
    Fang, Gang
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (03) : 357 - 362
  • [22] IDENTIFYING INDIVIDUALIZED MEDICATION ADHERENCE INTERVENTIONS BASED ON PREDICTIVE MODELS OBTAINED THROUGH A GROUP-BASED MULTI-TRAJECTORY APPROACH
    Pontinha, V
    Holdford, D.
    VALUE IN HEALTH, 2020, 23 : S286 - S286
  • [23] A graphical method to assess distribution assumption in group-based trajectory models
    Elsensohn, Mad-Helenie
    Klich, Amna
    Ecochard, Rene
    Bastard, Mathieu
    Genolini, Christophe
    Etard, Jean-Francois
    Gustin, Marie-Paule
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2016, 25 (02) : 968 - 982
  • [24] Smoothing Group-Based Trajectory Models Through B-Splines
    Francis B.
    Elliott A.
    Weldon M.
    Journal of Developmental and Life-Course Criminology, 2016, 2 (1) : 113 - 133
  • [25] Assessing the performance of group-based trajectory modeling method to discover patterns of medication adherence
    Diop, Awa
    Gupta, Alind
    Dron, Louis
    Mueller, Sabrina
    Smith, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 40 - 40
  • [26] Group-Based Trajectory Modeling: An Overview
    Nagin, Daniel S.
    ANNALS OF NUTRITION AND METABOLISM, 2014, 65 (2-3) : 205 - 210
  • [27] WHO WERE THE EARLY ADOPTERS OF DABIGATRAN? AN APPLICATION OF GROUP-BASED TRAJECTORY MODELS
    Lo-Ciganic, W.
    Gellad, W. F.
    Hiskamp, H. A.
    Choudhry, N. K.
    Zhang, R.
    Chang, C.
    Jones, B. L.
    Richards-Shubik, S.
    Guclu, H.
    Donohue, J. M.
    VALUE IN HEALTH, 2016, 19 (03) : A58 - A58
  • [28] Who Were the Early Adopters of Dabigatran? An Application of Group-based Trajectory Models
    Lo-Ciganic, Wei-Hsuan
    Gellad, Walid F.
    Huskamp, Haiden A.
    Choudhry, Niteesh K.
    Chang, Chung-Chou H.
    Zhang, Ruoxin
    Jones, Bobby L.
    Guclu, Hasan
    Richards-Shubik, Seth
    Donohue, Julie M.
    MEDICAL CARE, 2016, 54 (07) : 725 - 732
  • [29] The Impact of Missing Risk Factor Data on Semiparametric Group-Based Trajectory Models
    Ray, James V.
    Sullivan, Christopher J.
    Loughran, Thomas A.
    Jones, Shayne E.
    JOURNAL OF DEVELOPMENTAL AND LIFE-COURSE CRIMINOLOGY, 2018, 4 (03) : 276 - 296
  • [30] The Impact of Missing Risk Factor Data on Semiparametric Group-Based Trajectory Models
    James V. Ray
    Christopher J. Sullivan
    Thomas A. Loughran
    Shayne E. Jones
    Journal of Developmental and Life-Course Criminology, 2018, 4 : 276 - 296